Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.46 |
| ▸ | PI4KA | P42356 | 12/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 12/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 12/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 12/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27035498 | 0.85 | HDAC6 (0.35) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28480707 | 0.84 | CDK1 (0.47) | ADORA2AAHCY | |
| SCHEMBL7534078 | 0.82 | CYP1A2 (0.47) | — | |
| SCHEMBL580610 | 0.82 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL120720 | 0.81 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.80 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9014630 | 0.80 | FDPS (0.36) | EGFR | |
| SCHEMBL10460432 | 0.79 | ADORA2A (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28410735 | 0.78 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL6036330 | 0.75 | CDK1 (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178181-A1 | DEVICE AND METHOD FOR LABEL-FREE DETECTION OF DNA HYBRIDIZATION | WILLIAM MARCH RICE UNIVERSITY (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100249219-A1 | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA | SANTARIS PHARMA A/S (DK) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249219-A1 | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HIF-1ALPHA | HIF1AN, HIF1A, VHL | ADORA2A 1766/4885ADORA1 2087/4885PI4KA 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.